{"id":"gsk-biologicals-as01b-adjuvant","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain"},{"rate":"null","effect":"Redness"},{"rate":"null","effect":"Swelling"}]},"_chembl":{"chemblId":"CHEMBL4303308","moleculeType":"Small molecule","molecularWeight":"389.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AS01B adjuvant is a combination of the saponin QS-21 and the liposome-based 3-O-desacyl-4'-monophosphoryl lipid A (MPLA).","oneSentence":"Stimulates Toll-like receptor 4 and MyD88-dependent signaling pathway","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:39:51.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatitis B"},{"name":"Hepatitis E"}]},"trialDetails":[{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT02458092","phase":"PHASE1","title":"Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2008-04","conditions":"Malaria","enrollment":30},{"nctId":"NCT00397943","phase":"PHASE2","title":"Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-15","conditions":"Tuberculosis","enrollment":110},{"nctId":"NCT01157897","phase":"PHASE1, PHASE2","title":"Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2010-07","conditions":"Malaria, Plasmodium Vivax","enrollment":41},{"nctId":"NCT00434577","phase":"PHASE2","title":"Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-14","conditions":"Herpes Zoster","enrollment":715},{"nctId":"NCT00621322","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-03","conditions":"Tuberculosis","enrollment":180},{"nctId":"NCT00666380","phase":"PHASE1","title":"A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2008-04","conditions":"Malaria","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK Biologicals' AS01B adjuvant","genericName":"GSK Biologicals' AS01B adjuvant","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stimulates Toll-like receptor 4 and MyD88-dependent signaling pathway Used for Hepatitis B, Hepatitis E.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}